Current perspectives of treatment of ductal carcinoma in situ

Cancer Treatment Reviews

Volumn 36, Issue 7, 2010, Pages 507-517

  Estévez, Laura G ^a   Álvarez, Isabel ^b   Seguí, Miguel Ángel ^c   Muñoz, Monserrat ^d   Margelí, Mireia ^e   Miró, Cristina ^a   Rubio, Carmen ^a   Lluch, Ana ^f   Tusquets, Ignasi ^g  

^a Centro Integral Oncologico Clara Campal   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c Consorci Sanitari Parc Taulí ^*  (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g HOSPITAL DEL MAR   (Spain)

Author keywords

Ductal carcinoma in situ; Management; NSABP B 17 study; NSABP B 24 study; Prognosis; Radiology; Radiotherapy; Sentinel lymph node; Tamoxifen; UK ANZ study

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER INVASION; DUCTAL INFILTRATING CARCINOMA; ECHOMAMMOGRAPHY; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RECURRENCE RISK; REVIEW; SENTINEL LYMPH NODE BIOPSY; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMBINED MODALITY THERAPY; FEMALE; HUMANS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENTINEL LYMPH NODE BIOPSY; TAMOXIFEN;

EID: 77957965372     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.03.007     Document Type: Review

References (74)

1. Leonard G.D., Swain S.M. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004, 96:906-920.
2. Frykberg E.R., Bland K.I. Overview of the biology and management of ductal carcinoma in situ of the breast. Cancer 1994, 74:350-361.
3. Horner MJ, Krapcho M, Neyman N, Aminou R, Howlader N, et al., editors. SEER Cancer statistics review, 1975-2006, National Cancer Institute. Bethesda, MD. ; 2009. http://seer.cancer.gov/csr/1975_2006/.
4. Warnberg F., Nordgren H., Bergh J., Holmberg L. Ductal carcinoma in situ of the breast from a population-defined cohort: an evaluation of new histopathological classification systems. Eur J Cancer 1999, 35:714-720.
5. Kuerer H.M., et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol 2009, 27:279-288.
6. Vincent-Salomon A., et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res 2008, 14:1956-1965.
7. Xu S., Wei B., Zhang H., Qing M., Bu H. Evidence of chromosomal alterations in pure usual ductal hyperplasia as a breast carcinoma precursor. Oncol Rep 2008, 19:1469-1475.
8. Namba R., et al. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res 2006, 12:2613-2621.
9. Warnberg F., et al. Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. Breast Cancer Res 2006, 8:R21.
10. O'Sullivan M.J., Morrow M. Ductal carcinoma in situ - current management. Surg Clin North Am 2007, 87:333-351. [viii].
11. Brinton L.A., Sherman M.E., Carreon J.D., Anderson W.F. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 2008, 100:1643-1648.
12. Hofvind S., Sorum R., Thoresen S. Incidence and tumor characteristics of breast cancer diagnosed before and alter implementation of a population based screening-program. Acta Oncol 2008, 47:225-231.
13. Schouten van der Velden A.P., van Vugt R., van Duck J.A.A.M. Local recurrences after different treatment strategies for DCIS of the breast; a population-based study in the east Netherlands. Int J Radiat Oncol Biol Phys 2007, 3:703-710.
14. Boyages J., Delaney G., Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer 1999, 85:616-628.
15. Ernster V.L., Barclay J., Kerlikowske K., et al. Mortality among women with ductal carcinoma in situ of the breast in the population based surveillance, epidemiology, and end results program. Arch Int Med 2000, 160:953-958.
16. Boughey J.C., Gonzalez R.J., Bonner E., et al. Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist 2007, 12:1276-1287.
17. Burstein H.J., Polyak K., Wong J.S., et al. Ductal carcinoma in situ of the breast. N Engl J Med 2004, 350:1430-1441.
18. Fischer E., Constantino J., Fisher B., et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Cancer 1995, 75:1310-1319.
19. Julien J.P., Bijker N., Fentiman I.S., et al. Radiotherapy in breast conserving treatment fro ductal carcinoma in situ: first results of EORTC randomized phase III trial 10853. Lancet 2000, 355:528-533.
20. van de Vijver M.J. Biological variables and prognosis of DCIS. Breast 2005, 14:509-519.
21. Solin L.J., et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996, 14:754-763.
22. Rakovitch E., et al. Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy. J Clin Oncol 2007, 25:5591-5596.
23. Waldman F.M., et al. Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst 2000, 92:313-320.
24. Neuschatz A.C., et al. The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast. Cancer 2002, 94:1917-1924.
25. Silverstein M.J. An argument against routine use of radiotherapy for ductal carcinoma in situ. Oncology (Williston Park) 2003, 17:1511-1533. [discussion 1533-14, 1539, 1542 passim].
26. Wong J.S., et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 2006, 24:1031-1036.
27. Vicini F.A., Recht A. Age at diagnosis and outcome for women with ductal carcinoma-in-situ of the breast: a critical review of the literature. J Clin Oncol 2002, 20:2736-2744.
28. Fisher B., et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993, 328:1581-1586.
29. Fisher B., et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998, 16:441-452.
30. Fisher E.R., et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 1999, 86:429-438.
31. Julien J.P., et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000, 355:528-533.
32. Bijker N., et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006, 24:3381-3387.
33. Houghton J., et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003, 362:95-102.
34. Emdin S.O., et al. SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 2006, 45:536-543.
35. Fisher B., et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999, 353:1993-2000.
36. Namba R., et al. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res 2005, 7:R881-889.
37. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
38. Dignam J.J., Fisher B. Occurrence of stroke with tamoxifen in NSABP B-24. Lancet 2000, 355:848-849.
39. Fisher B., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005, 97:1652-1662.
40. Lyman G.H., et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005, 23:7703-7720.
41. Zujewski J., Eng-Wong J. Sentinel lymph node biopsy in the management of ductal carcinoma in situ. Clin Breast Cancer 2005, 6:216-222.
42. Moran C.J., Kell M.R., Kerin M.J. The role of sentinel lymph node biopsy in ductal carcinoma in situ. Eur J Surg Oncol 2005, 31:1105-1111.
43. Silverstein M.J., et al. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated?. Cancer 1994, 73:664-667.
44. Yiangou C., Shousha S., Sinnett H.D. Primary tumour characteristics and axillary lymph node status in breast cancer. Br J Cancer 1999, 80:1974-1978.
45. Mittendorf E.A., Arciero C.A., Gutchell V., Hooke J., Shriver C.D. Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. Curr Surg 2005, 62:253-257.
46. Wong J.H., Kopald K.H., Morton D.L. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg 1990, 125:1298-1301. [discussion 1301-292].
47. Silverstein M.J., et al. Axillary lymphadenectomy for intraductal carcinoma of the breast. Surg Gynecol Obstet 1991, 172:211-214.
48. Silver S.A., Tavassoli F.A. Mammary ductal carcinoma in situ with microinvasion. Cancer 1998, 82:2382-2390.
49. Klauber-DeMore N., et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion?. Ann Surg Oncol 2000, 7:636-642.
50. El-Tamer M., et al. Incidence and clinical significance of lymph node metastasis detected by cytokeratin immunohistochemical staining in ductal carcinoma in situ. Ann Surg Oncol 2005, 12:254-259.
51. Lara J.F., Young S.M., Velilla R.E., Santoro E.J., Templeton S.F. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer 2003, 98:2105-2113.
52. Tamhane R., Dahlstrom J.E., McCallum D.D., Buckingham J.M. The clinical significance of cytokeratin-positive cells in lymph nodes at the time of mastectomy from patients with ductal carcinoma-in-situ. Ann Surg Oncol 2002, 9:999-1003.
53. Bleiweiss I.J., Nagi C.S., Jaffer S. Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. J Clin Oncol 2006, 24:2013-2018.
54. Moore K.H., et al. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit. Ann Surg Oncol 2007, 14:2911-2917.
55. Wilkie C., White L., Dupont E., Cantor A., Cox C.E. An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. Am J Surg 2005, 190:563-566.
56. Jackman R.J., et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology 2001, 218:497-502.
57. Yen T.W., et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 2005, 200:516-526.
58. Dominguez F.J., et al. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ. Ann Surg Oncol 2008, 15:268-273.
59. Yi M., et al. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg 2008, 196:81-87.
60. Fraile M., et al. Is it possible to refine the indication for sentinel node biopsy in high-risk ductal carcinoma in situ?. Nucl Med Commun 2006, 27:785-789.
61. Yang W.T., Tse G.M. Sonographic, mammographic, and histopathologic correlation of symptomatic ductal carcinoma in situ. AJR Am J Roentgenol 2004, 182:101-110.
62. Soo M.S., Baker J.A., Rosen E.L. Sonographic detection and sonographically guided biopsy of breast microcalcifications. AJR Am J Roentgenol 2003, 180:941-948.
63. Santamaria G., Velasco M., Farrus B., Zanon G., Fernandez P.L. Preoperative MRI of pure intraductal breast carcinoma-a valuable adjunct to mammography in assessing cancer extent. Breast 2008, 17:186-194.
64. Sakorafas G.H., Farley D.R., Peros G. Recent advances and current controversies in the management of DCIS of the breast. Cancer Treat Rev 2008, 34:483-497.
65. Raza S., Vallejo M., Chikarmane S.A., Birdwell R.L. Pure ductal carcinoma in situ: a range of MRI features. AJR Am J Roentgenol 2008, 191:689-699.
66. Menell J.H., et al. Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging. Breast J 2005, 11:382-390.
67. Poellinger A., Diekmann S., Dietz E., Bick U., Diekmann F. In patients with DCIS: is it sufficient to histologically examine only those tissue specimens that contain microcalcifications?. Eur Radiol 2008, 18:925-930.
68. Zografos G.C., et al. Minimizing underestimation rate of microcalcifications excised via vacuum-assisted breast biopsy: a blind study. Breast Cancer Res Treat 2008, 109:397-402.
69. Zagouri F., et al. Vacuum-assisted breast biopsy: the value and limitations of cores with microcalcifications. Pathol Res Pract 2007, 203:563-566.
70. Polgar C., et al. The role of radiotherapy in the conservative treatment of ductal carcinoma in situ of the breast. Pathol Oncol Res 2008, 14:179-192.
71. Goodwin A. et al. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev 2009;4:CD000563.
72. Omlin A., et al. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol 2006, 7:652-656.
73. Allred D.C., et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992, 23:974-979.
74. Allred D.C., et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992, 10:599-605.